Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
150.27
+0.52 (0.35%)
Sep 5, 2025, 4:00 PM - Market closed
Krystal Biotech Stock Forecast
Stock Price Forecast
The 10 analysts that cover Krystal Biotech stock have a consensus rating of "Strong Buy" and an average price target of $204.9, which forecasts a 36.35% increase in the stock price over the next year. The lowest target is $166 and the highest is $245.
Price Target: $204.9 (+36.35%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $219 → $216 | Strong Buy | Maintains | $219 → $216 | +43.74% | Aug 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $240 | Strong Buy | Reiterates | $240 | +59.71% | Aug 22, 2025 |
| Citigroup | Citigroup | Hold Maintains $176 → $166 | Hold | Maintains | $176 → $166 | +10.47% | Aug 5, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $219 | Strong Buy | Maintains | $219 | +45.74% | Aug 5, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $219 | Strong Buy | Maintains | $219 | +45.74% | Jul 25, 2025 |
Financial Forecast
Revenue This Year
390.25M
from 290.52M
Increased by 34.33%
Revenue Next Year
576.96M
from 390.25M
Increased by 47.84%
EPS This Year
5.06
from 3.00
Increased by 68.73%
EPS Next Year
7.90
from 5.06
Increased by 56.00%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 412.9M | 730.7M | |||
| Avg | 390.3M | 577.0M | |||
| Low | 363.8M | 394.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 42.1% | 87.2% | |||
| Avg | 34.3% | 47.8% | |||
| Low | 25.2% | 1.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.45 | 10.07 | |||
| Avg | 5.06 | 7.90 | |||
| Low | 3.83 | 3.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 114.9% | 98.9% | |||
| Avg | 68.7% | 56.0% | |||
| Low | 27.7% | -25.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.